Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.49 |
| ▸ | PIM1 | P11309 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CTPS1 | P17812 | 11/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21044116 | 0.88 | PIM2 (0.40) | PIM2PIM3PIM1CYP19A1PIK3CD | |
| SCHEMBL21044410 | 0.84 | PIM1 (0.51) | PIM2PIM3PIM1CYP19A1CTPS1 | |
| SCHEMBL21044514 | 0.84 | CYP11B2 (0.49) | PIM2PIM3PIM1CYP19A1PIK3CD | |
| SCHEMBL24369654 | 0.82 | CTPS1 (0.45) | PIM2PIM3PIM1CYP19A1CTPS1 | |
| SCHEMBL21044113 | 0.81 | CYP11B2 (0.41) | PIM2PIM3PIM1PIK3CDPI4KB | |
| SCHEMBL21044338 | 0.81 | PIM2 (0.43) | PIM2PIM3PIM1CTPS1PIK3CD | |
| SCHEMBL30338504 | 0.80 | CTPS1 (0.46) | PIM2PIM3PIM1CYP19A1CTPS1 | |
| SCHEMBL4907728 | 0.80 | PIM1 (0.46) | PIM2PIM3PIM1CYP19A1CTPS1 | |
| SCHEMBL21044164 | 0.79 | PIM1 (0.50) | PIM2PIM3PIM1CTPS1PIK3CD | |
| SCHEMBL21387749 | 0.79 | CTPS1 (0.50) | PIM2PIM3PIM1CYP19A1CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-12466810-B2 | N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | STEP PHARMA S.A.S. (FR) | 2025-11-11 | — | — | US | disclosed |
| US-20250282756-A1 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2025-09-11 | — | — | US | disclosed |
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2025-07-29 | — | — | US | disclosed |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250066324-A1 | AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2025-02-27 | — | — | US | disclosed |
| US-11987573-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | STEP PHARMA S.A.S. (FR) | 2024-05-21 | — | — | US | disclosed |
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-114008039-B | Compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | 斯泰普制药股份公司 | 2024-01-16 | — | — | CN | disclosed |
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| CN-114008039-A | N- (5- (6-ethoxypyrazin-2-yl) pyridin-2-yl) -4- (2- (methylsulfonylamino) pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | 斯泰普制药股份公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210387965-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2021-12-16 | — | — | US | disclosed |
| CN-112839938-A | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2021-05-25 | — | — | CN | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| CN-111868051-A | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3543232-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2019-09-25 | — | — | EP | disclosed |
| EP-3543232-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2019-09-25 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371419-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | PIM2 1266/4885PIM3 1965/4885PIM1 1643/4885 |
| US-20250282756-A1 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | PIM2 1175/4885PIM3 1809/4885PIM1 1543/4885 |
| US-20250066324-A1 | AMINOPYRIMIDINE/PYRAZINE DERIVATIVES AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | PIM2 1266/4885PIM3 1965/4885PIM1 1643/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | PIM2 2031/4885PIM3 2231/4885PIM1 1525/4885 |
| US-20210387965-A1 | Compounds | CYP1A1, UGT1A1, CYP1B1 | PIM2 2384/4885PIM3 2551/4885PIM1 1667/4885 |
| US-11987573-B2 | Aminopyrimidine/pyrazine derivatives as CTPS1 inhibitors | CTPS1, CTPS2, TYMS | PIM2 1266/4885PIM3 1965/4885PIM1 1643/4885 |
| US-20210002269-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP19A1 | PIM2 2000/4885PIM3 2144/4885PIM1 1480/4885 |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | CTPS1, CTPS2, ECHS1 | PIM2 3060/4885PIM3 2957/4885PIM1 2993/4885 |
| US-12466810-B2 | N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2H-pyran-4-carboxamide derivatives and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases | CTPS1, CTPS2, TYMS | PIM2 2347/4885PIM3 1889/4885PIM1 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.